Screener
Jazz Pharmaceuticals JAZZ Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net income (loss) | $293.1 | $(92.5) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Intangible asset amortization | 172.3 | 154.4 |
| Share-based compensation | 74.5 | 67.7 |
| Acquisition accounting inventory fair value step-up adjustment | 37.5 | 29.9 |
| Provision for losses on accounts receivable and inventory | 14.2 | 5.3 |
| Depreciation | 9.1 | 10.4 |
| Non-cash interest expense | 4.7 | 17.1 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's stock-based comp?
- Jazz Pharmaceuticals (JAZZ) reported stock-based comp of $74.5M in Q1 2026.
- How has Jazz Pharmaceuticals's stock-based comp changed year-over-year?
- Jazz Pharmaceuticals's stock-based comp increased by 10.0% year-over-year, from $67.7M to $74.5M.
- What is the long-term trend for Jazz Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's stock-based comp has grown at a 11.4% compound annual growth rate (CAGR), from $189.01M to $291.13M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Jazz Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude